NCT00003744View on ClinicalTrials.gov

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions
Head and Neck Cancer
Interventions
DRUG

gemcitabine

Trial Locations (6)

37203

Sarah Cannon Research Institute, Nashville

60637-1470

University of Chicago Cancer Research Center, Chicago

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Harvard Pilgrim Health Care Institute, Boston

01805

Lahey Clinic, Burlington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00003744 - Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery | Biotech Hunter | Biotech Hunter